{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of belantamab mafodotin when administered intravenously in combination with pembrolizumab. PK parameter was determined using standard non-compartmental methods.","groups":[{"description":"Participants were administered belantamab mafodotin with recommended phase 2 dose (RP2D) of 2.5 mg/kg in combination with 200 mg of pembrolizumab via IV infusion on Day 1 of each 21-day Cycle up to until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles.","id":"OG000","title":"Main Study Phase- Part 2: Belantamab Mafodotin 2.5 mg/kg + Pembrolizumab 200 mg Expansion"}],"populationDescription":"Pharmacokinetic Population. Due to bioanalytical issues, PK data were not collected and analyzed for belantamab mafodotin. Therefore, this PK parameter was not reported in this study","reportingStatus":"POSTED","timeFrame":"EOI post belantamab mafodotin dose on Day 1 of each 21 day Cycle till Cycle 11","title":"Part 2 - C-EOI for Belantamab Mafodotin","type":"SECONDARY"}